Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · §2

Draft policy: labelling of Institute-constructed programme… — submissions

The 13 submissions received, published in full with declared interests and secretariat responses.

Document identifier
CEI-CP-013/2
Series
Public comment period
Version
1.0
Published
05 Jan 2025
Last reviewed
05 Jan 2025
Next review
05 Jan 2026
Identifier
10.71829/cei.cp.13
Certainty
Not rated
Cycle
2024 Q4
Window
01 Nov 2024 – 01 Dec 2024
Status
Closed
Submissions
13

§2Submissions and responses

13 submissions were received. Each is published in full below with its declared interest, the secretariat response and the disposition. The Institute publishes submissions it did not accept in the same form as those it did.

Dr Melisande Thorsby-Nakamura, PhD (Medicinal Chemistry) University department of public health
DRAFT-PROGRAMME-RE/013 received 02 Nov 2024

The position of a contributor who withdraws consent is not stated

The respondent states that consent to be named is obtained at submission and that the policy is silent on what happens if it is later withdrawn, which leaves both the Institute and the contributor without a rule.

The respondent proposes that the position be stated in advance and be the same for everyone.

Declared interest. Employed by a national competent authority. This submission is made in a personal capacity and does not represent the position of that authority.
Secretariat responseAccepted08 Dec 2024

The secretariat accepts this submission. A rule made at the point of the first withdrawal is a rule made about a particular person.

The policy now states that a contributor may withdraw from the register at any time and that the register entry is removed, while a signed submission already published remains published, because the consultation record is a record of what was said and by whom. The position is stated at the point consent is given.

Dr Zebedee Zaleski-Mbeki, PhD (Pharmaceutics) Endocrine surgery service
DRAFT-PROGRAMME-RE/001 received 17 Nov 2024

A party criticised in an assessment should have a right of reply

The respondent states that a supplier or sponsor whose documentation is assessed adversely has no route to respond other than a comment period that may not be open.

The respondent proposes a standing right of reply published alongside the assessment.

Declared interest. Is a practising clinician who prescribes compounds in the class under assessment. No financial relationship with any manufacturer.
Secretariat responseAccepted in part21 Dec 2024

The secretariat accepts this submission in part. A route to submit a correction of fact is opened at any time and is not dependent on a consultation window. A general right of reply published alongside the assessment is not adopted, because it would give an assessed party the last word on the Institute's own document.

A standing correction route is now published, corrections of fact are assessed and applied at any time with the change recorded in the amendment log, and a submission of substance received outside a window is held and published in the next comment period on that document.

Dr Amara Quaresma, MD, MRCP Independent analytical consultancy
DRAFT-PROGRAMME-RE/005 received 19 Nov 2024

Declared interests should appear on the document rather than on a separate page

The draft links to a central conflicts register. The respondent argues that a reader assessing whether to rely on a particular document should not have to leave it to find out who assessed it and what they declared.

The respondent proposes that the interests of every named contributor to a document be printed on that document.

Declared interest. Employed by a university department that has received unrestricted research funding from a manufacturer of a compound in the class under assessment. The respondent had no role in that funding.
Secretariat responseNoted, no amendment09 Dec 2024

The secretariat notes this submission and records that the draft already provides for it, which the respondent could reasonably have missed because the provision sits in an appendix.

Every document carries the declared interests of its named contributors in its front matter, and the central register exists so that a reader can see a person across all documents rather than one at a time. No amendment arises; the provision has been moved from the appendix into the body of the methodology document so that it is findable.

Dr Georgiana Zimmerthal, PhD (Biostatistics) University department of medicinal chemistry
DRAFT-PROGRAMME-RE/010 received 19 Nov 2024

A sortable table implies a comparison the underlying data do not support

The draft presents a sortable table whose columns are drawn from sources of differing quality. The respondent states that sorting on such a column produces an ordering that looks like a ranking and is not one.

The respondent proposes that sorting be disabled on any column whose values are not commensurable.

Declared interest. Employed by a national competent authority. This submission is made in a personal capacity and does not represent the position of that authority.
Secretariat responseNoted, no amendment30 Dec 2024

The secretariat notes this submission and records that the point is correct in principle.

No amendment arises here because every sortable table in the document set already carries a standing statement above it that the ordering is not a ranking and that the values in each column are commensurable only where the column header says so. The proposal to disable sorting was considered and not adopted, because a reader who cannot sort a table generally sorts it elsewhere and without the statement.

Dr Sigrún Lavrentiev, PhD (Toxicology) Health-technology assessment agency · industry submission
DRAFT-PROGRAMME-RE/012 received 19 Nov 2024

The disclosure requirements exceed those of comparable bodies

The submission is made on behalf of a manufacturer. It states that the per-page disclosure requirement is more extensive than that applied by comparable assessment bodies and that the repetition may be read as implying a relationship of greater significance than exists.

The submission does not object to disclosure and objects to its placement and frequency.

Declared interest. Is an employee of a marketing-authorisation holder for a compound named in the draft. This submission is made on behalf of that company and is identified as an industry submission throughout.
Secretariat responseNoted, no amendment14 Dec 2024

The secretariat notes this submission and records that the point about repetition is a fair one.

No amendment arises. Per-page disclosure was consulted on separately and retained, on the ground that a reader arriving at a single page from a search engine does not see a disclosure held elsewhere. The wording has been standardised so that the repeated statement is identical at every occurrence and is not read as a series of different claims. The submission is identified as an industry submission.

Dr Ottoline Fitzgerald-Nwosu, MD, MRCP Independent analytical consultancy
DRAFT-PROGRAMME-RE/002 received 21 Nov 2024

The secretariat answers submissions and is not itself named

The respondent states that responses are attributed to the secretariat as a body, and that a reader cannot tell who wrote a response or whether that person had a relevant interest.

The respondent proposes that responses be signed individually.

Declared interest. Has previously served as an investigator on a trial included in the evidence base under consultation. Received no personal payment; institutional payment was made to the trial site.
Secretariat responseAccepted in part07 Dec 2024

The secretariat accepts this submission in part. Responses are attributed to the named members of the secretariat responsible for the document rather than to individuals per response, and the interests of those members are published.

Every comment period now names the secretariat members responsible for it, with their declared interests, in the consultation front matter, so that the responses can be read against the interests of the people who wrote them.

Yusuf Whitmarsh-Obi, PhD (Medicinal Chemistry) University department of public health · industry submission
DRAFT-PROGRAMME-RE/006 received 23 Nov 2024

The document should not describe uses outside the approved indication

The submission is made on behalf of a marketing-authorisation holder. It states that the draft describes uses of the compound that fall outside the approved indication, that such uses are not supported by the sponsor, and that describing them may be read as legitimising them.

The sponsor asks that the sections concerned be removed, or in the alternative that they carry a prominent statement that the sponsor does not support such use.

Declared interest. Is an employee of a marketing-authorisation holder for a compound named in the draft. This submission is made on behalf of that company and is identified as an industry submission throughout.
Secretariat responseNot accepted24 Dec 2024

The secretariat does not accept this submission. The Institute records what is supplied and what is used, because a reader encountering a compound outside a regulated route is the reader most in need of an assessment of the evidence for it.

The sections remain. Every such section already states the regulatory status of the use described and states that the evidence for it is assessed separately from the evidence for the approved indication. The submission is published in full and identified as an industry submission.

Dr Beatrijs Hazelrigg, PhD (Chemistry), MRSC University department of pharmacy practice
DRAFT-PROGRAMME-RE/009 received 23 Nov 2024

The same concept is given three different names in one document

The draft refers to the same quantity as a response rate, a responder proportion and a categorical outcome in different sections. The respondent, who works in health-technology assessment, states that a reader cannot tell whether the three refer to one thing or to three.

The respondent proposes that the glossary term be used at every occurrence and that the glossary entry be linked at first use in each section rather than only at first use in the document.

Declared interest. No financial interest. Has published a systematic review reaching a different conclusion from the draft, which the respondent declares as a non-financial interest.
Secretariat responseAccepted15 Dec 2024

The secretariat accepts this submission. The variation was stylistic and its cost to the reader exceeds any benefit.

A single term is now used throughout for each defined concept, and the glossary entry is linked at first use within each section rather than once per document.

Radoslava Palmgren-Kofi, PhD (Medicinal Chemistry) University department of public health
DRAFT-PROGRAMME-RE/011 received 24 Nov 2024

A superseded version should remain reachable from the version that replaced it

The respondent states that the draft supersedes an earlier document and that a reader who cited the earlier version has no way to reach it from the new one, which makes it impossible to see what changed.

The respondent asks that every version carry a link both to what it supersedes and to what supersedes it.

Declared interest. No interest to declare. The respondent is a graduate student and states that the submission forms no part of any assessed work.
Secretariat responseNoted, no amendment30 Dec 2024

The secretariat notes this submission. The corrections and versioning policy already requires bidirectional version links and every superseded document is retained at its own address.

No amendment arises. The requirement is stated in the corrections and versioning policy and the amendment log of this document links to the version it replaced. The respondent is correct that the link was absent from the draft page furnished for consultation, which was a defect of the consultation copy and not of the policy.

Dr Yolanda Norrington-Bhatt, BPharm, PhD National pharmacovigilance centre
DRAFT-PROGRAMME-RE/007 received 25 Nov 2024

The terms on which the documents may be reused are not stated

The respondent, a librarian, states that the site carries no statement of reuse terms and that an assessment which cannot be quoted with confidence will be paraphrased instead, which is worse for accuracy.

The respondent proposes an explicit reuse statement.

Declared interest. Has received travel support to attend a scientific meeting from a manufacturer of a compound named in the draft.
Secretariat responseAccepted13 Dec 2024

The secretariat accepts this submission. An unstated position on reuse is a position that will be guessed at.

The reuse terms are now stated explicitly on the legal page and in the document footer, permitting quotation and reproduction with attribution and the document version, and requiring that any reproduction carry the certainty rating that accompanied the quoted statement.

Dr Wolfram Kaltenbach-Mensah, PhD (Toxicology) Health-technology assessment agency
DRAFT-PROGRAMME-RE/003 received 26 Nov 2024

The document is unreadable without specialist training

The respondent, a trustee of a patient organisation, states that the draft is written for a reader who already understands certainty grading, and that the people most affected by the subject matter will not reach the assessment at all.

The respondent proposes a plain-language summary at the head of every document, written to the same standard of accuracy as the document itself and not as a promotional abstract.

Declared interest. Holds a personal shareholding, below the Institute's materiality threshold, in a diversified fund with pharmaceutical sector exposure. No direct holding in any named company.
Secretariat responseAccepted in part18 Dec 2024

The secretariat accepts this submission in part. A plain-language summary is added. The proposal that it replace the technical abstract is declined, because the abstract is the part of the document other assessors read and cite.

Every document now opens with a plain-language summary of not more than 150 words, placed above the technical abstract and carrying the same certainty language, so that the two cannot diverge.

Dr Katarzyna Yorkstone, MD, MRCP Independent analytical consultancy
DRAFT-PROGRAMME-RE/008 received 28 Nov 2024

The document should state what a reader ought to do

The draft assesses evidence and stops. The respondent, a practising clinician, states that a reader arriving at the document with a decision to make is left to convert an assessment into an action without help, and proposes that each document close with a recommendation.

The respondent argues that other evidence bodies issue recommendations and that declining to do so transfers the difficult part of the work to the reader.

Declared interest. No financial or non-financial interest to declare in relation to the subject of this consultation.
Secretariat responseNot accepted24 Dec 2024

The secretariat does not accept this submission, and records that the point is a reasonable one rather than a misunderstanding.

The Institute assesses evidence and does not issue recommendations, because a recommendation embeds values and a resource context that the Institute does not hold and cannot state. That constitutional limit is published on the methodology page and is not varied by consultation. The submission remains published in full.

Quentin Gwynne-Sarpong, MD, DPhil Metabolic medicine service, tertiary centre
DRAFT-PROGRAMME-RE/004 received 30 Nov 2024

Recusal should follow automatically from any declared financial interest

The respondent states that case-by-case recusal decisions require the body making them to judge its own members, and that an automatic rule removes the judgement and with it the appearance of partiality.

The respondent proposes automatic recusal on any declared financial interest in a named company.

Declared interest. Employed by an analytical laboratory that performs contract testing for suppliers, including at least one supplier named in the Institute's assessment set.
Secretariat responseNot accepted15 Dec 2024

The secretariat does not accept this submission. An automatic rule of that breadth would recuse most of the people competent to assess the evidence, and the Institute would be left with assessors chosen for their distance from the field.

Recusal remains determined against the specific document, with the decision, its reasons and the person recused published in the document front matter. The submission is published in full because it identifies a genuine tension the Institute has resolved in one direction rather than removed.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.